| Cat.No. | Name | Information |
|---|---|---|
| M43522 | NSC194598 | NSC194598 is a p53 DNA-binding inhibitor with IC50 value of 180 nM and 2-40 μM for in vitro and in vivo, respectively. |
| M10964 | TPX-0046 | TPX-0046 is a novel RET/SRC inhibitor that is used against RET in Ba/F3 cell proliferation assaysG810R The average IC50 is 17 nM. |
| M10934 | BBT594 | BBT594 IS A POTENT RECEPTOR TYROSINE KINASE RET INHIBITOR COMMONLY USED IN CANCER RESEARCH. |
| M10933 | GSK3179106 | GSK3179106 is an orally active, selective RET kinase inhibitor for human and rat RET IC50 0.4 nM and 0.2 nM, respectively. GSK3179106 has the potential for use in irritable bowel syndrome (IBS) by reducing post-inflammatory and stress-induced visceral hypersensitivity reactions. |
| M10932 | AST 487 | AST 487 is a RET kinase inhibitor,IC50 880 nM, inhibits RET autophosphorylation, downstream effector activation, and also inhibits Flt-3,IC50 520 nM. |
| M10375 | AD80 | AD80 is a multikinase inhibitor, it potently targets human RET, BRAF, S6K, and SRC. |
| M9900 | Selpercatinib (LOXO-292) | Selpercatinib (LOXO-292) is a first-in-class, highly selective and potent small molecule RET inhibitor with good blood-brain barrier (BBB) penetration. and RET (G810R) with IC50 values of 14.0 nM, 24.1 nM and 530.7 nM, respectively. |
| M9346 | Pralsetinib | Pralsetinib (BLU-667) is a next generation highly potent, selective RET inhibitor with IC50 of 0.3-0.4 nM for WT RET, RET mutants V804L, V804M, M918T and CCDC6-RET fusion. |
| M8536 | SPP86 | SPP86 is a potent cell permeable inihbitor of RET tyrosine kinase with an IC50 value of 8 nM and with some inhibitory activity at EphA1, FGFR1, Flt4, Lck and Yes. |
| M8146 | RPI-1 | RPI-1 is a competitive, potent ATP-dependent Ret kinase inhibitor. |
| M57211 | Zeteletinib | Zeteletinib (BOS-172738; DS-5010) is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. |
| M57210 | Zeteletinib hemiadipate | Zeteletinib (BOS-172738; DS-5010) hemiadipate is an orally active, selective RET kinase inhibitor with nanomolar potency against RET and >300-fold selectivity against VEGFR2. |
| M49837 | RET V804M-IN-1 | RET V804M-IN-1 is a wt-RET -selective inhibitors of RETV804M kinase, with an IC50 of 20 nM. |
| M43523 | Multi-kinase-IN-5 | Multi-kinase-IN-5 is a promising multi-kinase inhibitory agent. |
| M43521 | RET-IN-22 | RET-IN-22 is a potent, selective and orally active RET inhibitor with an IC50 of 20.9 nM and 18.3 nM for wild-type RET and RET-V804M, respectively. |
| M43520 | RET-IN-23 | RET-IN-23 is a potent and orally active RET inhibitor with IC50 values of 1.32, 2.50, 6.54, 1.03, 1.47 nM for RET-WT, RET-CCDC6, RET-V804L, RET-V804M, RET-M918T, respectively. |
| M39846 | Pyrazoloadenine | Pyrazoloadenine is a potent RET (REarranged during Transfection) lung cancer oncoprotein inhibitor. Pyrazoloadenine shows anticancer activity. |
| M30921 | BT44 | BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus. |
| M29529 | Enbezotinib | Enbezotinib, an inhibitor of RET, can inhibit the RET autophosphorylation. Enbezotinib can be used for the research of cancer. |
| M29373 | RET-IN-1 | RET-IN-1 is a RET kinase inhibitor, with IC50 values of 1 nM, 7 nM, and 101 nM for RET (WT), RET (V804M) , and RET (G810R), respectively . |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
